Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILENCE-TTR: Vutrisiran vs TTR Stabilizers in ATTR Cardiomyopathy
jRCT1051250227Recruiting
- Start
- Jan 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Randomised trial of vutrisiran in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (2 arms), sponsored by none. Started Jan 2026; status: recruiting.
02
Drugs
vutrisiran
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT1051250227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250227.